Comparison of in vivo outcome following transfusion of dynamic light scattering-screened versus unscreened platelets in hematologic malignancy: A randomised controlled trial

Vancouver Coastal Health (Canada)0 个研究点目标入组 200 人开始时间: 2010年7月16日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•We propose to enrol 200 leukemia and bone marrow transplant inpatients, as frequent recipients of prophylactic and therapeutic platelet transfusions.
•All patients >18 years of age with hematologic malignancies on the leukemia and bone marrow transplant ward VGH (T15), undergoing stem cell transplantation or chemotherapy, and expected to require at least one platelet transfusion will be considered for enrolment.

•1. Patients who have received platelet transfusion (outside the CoDIVO study) within the past two weeks
•2. Patients known to require Human Leukocyte Antigen (HLA) matched platelet support will be ineligible, due to TML's inability to guarantee availability of HLA matched platelets with TL score >15 in experimental arm
•3. Patients with documented splenomegaly will be excluded, because an enlarged spleen causes enhanced platelet removal
•4. Unable to provide informed consent
•5. Unreliable availability of appropriate English translator (Daily bleeding scores required)
•6. Pregnancy
•7. Major surgery within the previous two weeks
•8. Acute promyelocytic leukemia
•9. Idiopathic or Thrombotic thrombocytopenic purpura or Hemolytic Uremic Syndrome

发起方

Vancouver Coastal Health (Canada)